Atlas FDA

COBAS KRAS MUTATION TEST

FDA premarket approval P140023/S004 · decided 2016-09-24

Approval details

PMA number
P140023
Supplement
S004
Supplement type
Normal 180 Day Track
Supplement reason
Labeling Change - Indications/instructions/shelf life/tradename
Trade name
COBAS KRAS MUTATION TEST
Generic name
Somatic gene mutation detection system
Applicant
Roche Molecular Systems, Inc.
Date received
2016-02-29
Decision date
2016-09-24
Days to decision
208 days
Decision code
APPR
Product code
OWD
Advisory committee
Pathology
Expedited review
No
Location
Pleasanton, CA
Statement
The cobas® KRAS Mutation Test, for use with the cobas® 4800 System, is a real-time PCR test for the detection of mutations in codons 12, 13 and 61 of the KRAS gene in DNA derived from formalin-fixed paraffin-embedded human colorectal cancer (CRC) tumor tissue. The test is intended to be used as an aid in the identification of CRC patients who should not be treated with Erbitux® (cetuximab) or with Vectibix® (panitumumab) when KRAS Codon 12 or 13 mutation is detected. Safety and efficacy of Erbit

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
cobas® BV/CV (K260021)Roche Molecular Systems, Inc.2026-07-16
cobas CT/NG for use on the cobas 5800/6800/8800 systems; cobas TV/MG for use on the cobas 5800/6800/8800 systems (K260917)Roche Molecular Systems, Inc.2026-07-08
cobas liat CT/NG/MG nucleic acid test (K253759)Roche Molecular Systems, Inc.2026-05-15
cobas liat CT/NG nucleic acid test (K253756)Roche Molecular Systems, Inc.2026-05-15
cobas liat Bordetella panel nucleic acid test (K243753)Roche Molecular Systems, Inc.2025-11-20
cobas CMV (K252481)Roche Molecular Systems, Inc.2025-11-03
cobas HCV (K252484)Roche Molecular Systems, Inc.2025-11-03
cobas Respiratory 4-flex for use on the cobas 5800/6800/8800 Systems (K243455)Roche Molecular Systems, Inc.2025-07-31